The exception was lower grade glioma (LGG), where PORPOISE’s focus on gene mutations, such as the IDH1 mutation status29 provided an advantage, whereas PROGPATH utilized only age and sex information, because LGG does not use a conventional staging system. Here, IDH1 is linked to central nervous system cancer.